Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic V… (NCT07410143) | Clinical Trial Compass
Active — Not RecruitingPhase 1/2
Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions
United Kingdom1 participantsStarted 2026-01-13
Plain-language summary
This study is being conducted to evaluate individualised antisense oligonucleotides (ASOs) in participants with severely debilitating, life threatening (SDLT) central nervous system (CNS) conditions caused by unique genetic variants amenable to correction by an ASO.
Who can participate
Age range1 Year
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The first participant receiving the individualised ASO, must be between 1 and 17 years of age (inclusive) at the time they receive their first ASO dose.
✓. The CNS condition is severely debilitating and/or life threatening.
✓. The identified genetic variant is unique.
✓. The identified genetic variant is considered the underlying cause of disease.
✓. The identified genetic variant is amenable to correction by an ASO.
✓. In the opinion of the investigator, the disease is at a stage that, if halted or slowed by treatment with the individualised ASO, has a reasonable chance to improve the participant's overall disease burden/impact on quality of life.
✓. In the opinion of the investigator, participant, and/or the participant's legally authorised representative, existing therapies have not resulted in meaningful benefit.
Exclusion criteria
✕. Known history or presence of any clinically significant hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, or haematological disease or condition other than the primary disease for which the individualised ASO is being developed that in the opinion of the Investigator could affect patient safety or interfere with study outcomes.
✕. Any contraindication to brain MRI scans.
✕. Any contraindication to sedation or anaesthesia.
What they're measuring
1
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)